TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03620552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-S16
Description: A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
Study: NCT00712530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir
Description: DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir
Description: DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir
Description: DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Study: NCT02921555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
Study: NCT00002849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: first 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
Study: NCT02094742

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Study: NCT02781025

Intervention type: OTHER
Intervention: Blood draw
Description: A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
Study: NCT03756363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-solvent
Description: Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Solvent
Description: Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
Study: NCT03243214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Real or Sham TMS will be given to the PD-MCI patient

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-TMS
Description: Real or Sham TMS will be given to the PD-MCI patient
Study: NCT03029195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding therapy
Description: Presurgical infant orthopedics
Study: NCT00681694

Intervention type: RADIATION
Intervention: brachytherapy
Description: An experimental arm using MRI imaging and excluding the transition zone from the target volume

Intervention type: RADIATION
Intervention: brachytherapy
Description: Standard ultrasound-guided brachytherapy with standard target volumes

Intervention type: RADIATION
Intervention: brachytherapy
Description: Standard ultrasound-guided brachytherapy with standard target volumes
Study: NCT01543672

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 3-5 fractions within 10-14 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 3-5 fractions per tumor within one treatment session or sequential within one month
Study: NCT01228604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate (Ritalin®)
Description: The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
Study: NCT02073838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT02076360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Video
Description: Patients will watch preoperative instructional video
Study: NCT01780714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarettes (CC)
Description: Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.1
Description: Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
Study: NCT02299570

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX2660 (microbiota suspension)
Description: A suspension of intestinal microbes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX2660 (microbiota suspension)
Description: A suspension of intestinal microbes
Study: NCT01580189

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: 55-65g maltodextrin solution, immediately after training, 9 weeks
Study: NCT02031926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure
Study: NCT03963362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 75 mg
Description: GLARS-NF3 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 75 mg
Description: GLARS-NF3 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 75 mg
Description: GLARS-NF3 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 150 mg
Description: GLARS-NF3 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 150 mg
Description: GLARS-NF3 tablet
Study: NCT03569540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Placebo-controlled; Double blind test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amylum
Study: NCT03439020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plastic stent anchoring
Description: Insert an additional plastic stent to anchor the fully covered self expandable metal stent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS
Description: Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FCSEMS
Description: Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
Study: NCT01120912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi Oral Insulin
Description: Oral insulin single administration
Study: NCT03344432

Intervention type: DIAGNOSTIC_TEST
Intervention: with intraocular pressure high
Description: Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.

Intervention type: DIAGNOSTIC_TEST
Intervention: with intraocular pressure high
Description: Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
Study: NCT02299570

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A suspension of saline and cryoprotectant
Study: NCT03344432

Intervention type: DIAGNOSTIC_TEST
Intervention: without intraocular pressure high
Description: Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.

Intervention type: DIAGNOSTIC_TEST
Intervention: without intraocular pressure high
Description: Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
Study: NCT02977689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Description: study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
Study: NCT02299570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A suspension of saline and cryoprotectant
Study: NCT02120092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 1x Loading dose 600 mg 6x maintenance dose 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 1x Loading dose 600 mg 6x maintenance dose 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: 1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7x 300mg acetylsalicylic acid placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7x 300mg acetylsalicylic acid placebo
Study: NCT04015037

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: placebo or drug
Description: Group A and B (medicated or placebo)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: placebo or drug
Description: Group A and B (medicated or placebo)
Study: NCT01851486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 0.15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 0.15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: naloxone 0.15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: naloxone 0.15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT03473964

Intervention type: DRUG
Intervention: H.P. Acthar gel
Description: H.P. Acthar gel:~Injection 40 mg twice weekly
Study: NCT01932151

Intervention type: DRUG
Group type: OTHER
Intervention: Terlipressin and albumin
Description: Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water.
Study: NCT03466619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inflatable penile prosthesis (IPP)
Description: inflatable penile prosthesis (IPP)
Study: NCT01161095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Description: Mirena (Bayer)- Levonorgestrel-Intrauterine System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: Mirena (Bayer)- Levonorgestrel-Intrauterine System
Study: NCT01161550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT01397123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training teachers on healthier lifestyles
Description: During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
Study: NCT01806324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL040XC
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan + Atorvastatin
Description: Single dose
Study: NCT03582072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: letter from the CMO
Description: informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
Study: NCT02678845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment according to the Collabri model
Description: The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
Study: NCT04388267

Intervention type: DRUG
Intervention: Fluid challenge
Description: All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min.

Intervention type: DRUG
Intervention: Fluid challenge
Description: All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min.
Study: NCT03724539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRIPA intervention
Description: STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices.
Study: NCT01161550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Study: NCT00517439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: 1000/1200mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 90 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 90 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 90 micrograms sc weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 1000mg po bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 1000mg po bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 500mg po bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 500mg po bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 500mg po bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4588161
Description: 1500mg po bid for 24 weeks
Study: NCT02640625

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic compound
Description: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
Study: NCT02877654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy with biopsies in the left colon to assess intestinal permeability
Description: Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit).
Study: NCT00824551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2 sessions of HBOT ( HDMC 14)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient will undergo standard care